The China Securities Regulatory Commission has approved the IPO registration of Beixin Life Science on the GEM board.

On December 18th, the China Securities Regulatory Commission released the approval for the initial public offering of Shenzhen North-Bank Life Science and Technology Co., Ltd. It is reported that North-Bank Life intends to go public on the Shanghai Stock Exchange's Science and Technology Innovation Board, with CICC as the sponsor institution, aiming to raise 952 million yuan. The prospectus shows that North-Bank Life is a national high-tech enterprise focusing on the research, development, production, and sales of precision diagnosis and treatment equipment for cardiovascular diseases. The company is committed to developing precise solutions that bring revolutionary changes to the diagnosis and treatment of cardiovascular diseases. The company's core products include China's first domestically produced 60MHz high-definition high-speed IVUS diagnostic system approved by the National Medical Products Administration, and the core product FFR measurement system for blood flow reserve score, which is the first domestically produced product approved by the National Medical Products Administration in the FFR field. Both of these products have entered the national Innovative Medical Management equipment special review process and are expected to bring revolutionary changes to the clinical practice of guiding percutaneous coronary intervention (PCI) surgery. The company is the first domestic medical device company to have a combination of intravascular functional FFR and imaging IVUS products, filling the gap in the domestic market and rewriting the reliance on imported products for the precise diagnosis of coronary artery diseases in China. The company has established a high-performance and high-barrier active intervention medical device product realization system, continuously achieving successful research and development and commercialization of innovative products, and has gained recognition in both domestic and international markets and clinical settings.